Grand Life Sciences

Explore the latest insights on Grand Life Sciences and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Grand Life Sciences’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Grand Life Sciences, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Grand Life Sciences please access flcube.com

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Limited (HKG: 2137) announced the launch of its proprietary BRiSC (Bispecific RNAi iSilenCing) small interfering RNA (siRNA) drug discovery platform, designed to advance the development of next‑generation ribonucleic…

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market
CompanyDeals

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China
CompanyDeals

CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China
CompanyDeals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China
CompanyDeals

TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China

CompanyDeals

Zelgen Biopharmaceuticals Partners with Grand Life Sciences for Exclusive Marketing of Recombinant Human Thrombin